1. Obituary

   Obituary 25 November 2010 Pages: 1 - 3

   

2. Phase I study of intraperitoneal irinotecan in patients with gastric adenocarcinoma with peritoneal seeding

   • Moon Ki Choi
   • Byung-Jin Ahn
   • Won Ki Kang

   Original Article 06 March 2010 Pages: 5 - 11

   

3. Erucylphospho-N,N,N-trimethylpropylammonium (erufosine) is a potential antimyeloma drug devoid of myelotoxicity

   • Deyan Y. Yosifov
   • Plamen T. Todorov
   • Martin R. Berger

   Original Article 23 February 2010 Pages: 13 - 25

   

4. Penetration of ifosfamide and its active metabolite 4-OH-ifosfamide into cerebrospinal fluid of patients with CNS malignancies

   • Philipp Kiewe
   • Martin Neumann
   • Agnieszka Korfel

   Original Article 24 February 2010 Pages: 27 - 33

   

5. Phase II study of erlotinib for chemotherapy-naïve patients with advanced or metastatic non-small cell lung cancer who are ineligible for platinum doublets

   • Dae Ho Lee
   • Sang-We Kim
   • Jung-Shin Lee

   Original Article 25 February 2010 Pages: 35 - 39

   

6. Sequential chemotherapy with dose-dense docetaxel, cisplatin, folinic acid and 5-fluorouracil (TCF-dd) followed by combination of oxaliplatin, folinic acid, 5-fluorouracil and irinotecan (COFFI) in metastatic gastric cancer: results of a phase II trial

   • Matteo Dalla Chiesa
   • Gianluca Tomasello
   • Rodolfo Passalacqua

   Original Article 05 March 2010 Pages: 41 - 48

7. DPD-based adaptive dosing of 5-FU in patients with head and neck cancer: impact on treatment efficacy and toxicity

   • Chen Guang Yang
   • Joseph Ciccolini
   • Cédric Mercier

   Original Article 05 March 2010 Pages: 49 - 56

8. Pharmacokinetic and pharmacodynamic study of two doses of bortezomib in patients with relapsed multiple myeloma

   • Donna E. Reece
   • Dan Sullivan
   • A. Keith Stewart

   Original Article 20 March 2010 Pages: 57 - 67

   

9. Biweekly vinorelbine and gemcitabine as second-line and beyond treatment in ovarian cancer

   • N. Xenidis
   • K. Neanidis
   • S. Kakolyris

   Original Article 11 March 2010 Pages: 69 - 73

   

10. Phase II trial of induction irinotecan-cisplatin followed by concurrent irinotecan-cisplatin and radiotherapy for unresectable, locally advanced gastric and oesophageal-gastric junction adenocarcinoma

    • Fernando Rivera
    • Maica Galán
    • On Behalf of the Spanish Cooperative Group for Digestive Tumour Therapy (TTD)

    Original Article 03 March 2010 Pages: 75 - 82

    

11. The histone deacetylase inhibitor valproic acid sensitizes human and canine osteosarcoma to doxorubicin

    • Luke A. Wittenburg
    • Liam Bisson
    • Douglas H. Thamm

    Original Article 20 March 2010 Pages: 83 - 92

    

12. An exploratory study of body composition as a determinant of epirubicin pharmacokinetics and toxicity

    • Carla M. M. Prado
    • Isac S. F. Lima
    • Michael B. Sawyer

    Original Article 05 March 2010 Pages: 93 - 101

    

13. The antioxidant ascorbic acid mobilizes nuclear copper leading to a prooxidant breakage of cellular DNA: implications for chemotherapeutic action against cancer

    • M. F. Ullah
    • H. Y. Khan
    • S. M. Hadi

    Original Article 06 March 2010 Pages: 103 - 110

    

14. Serological immune responses to influenza vaccine in patients with colorectal cancer

    • Ajithkumar Puthillath
    • Donald L. Trump
    • Marwan G. Fakih

    Original Article 05 March 2010 Pages: 111 - 115

    

15. Pioglitazone modulates tumor cell metabolism and proliferation in multicellular tumor spheroids

    • Eva Gottfried
    • Sebastian Rogenhofer
    • Marina Kreutz

    Original Article 09 March 2010 Pages: 117 - 126

    

16. Clinical characteristics and treatment outcomes of gastric cancer patients with isolated para-aortic lymph node involvement

    • In Hae Park
    • Sun Young Kim
    • Sook Ryun Park

    Original Article 11 March 2010 Pages: 127 - 136

    

17. Characterization of the in vitro activity of AZD3409, a novel prenyl transferase inhibitor

    • Natalie M. G. M. Appels
    • Maria J. Bolijn
    • Jan H. M. Schellens

    Original Article 13 March 2010 Pages: 137 - 145

    

18. Phase II study of FOLFIRI regimen in patients with advanced colorectal cancer refractory to fluoropyrimidine and oxaliplatin

    • Han Ying Bao
    • Wei Jia Fang
    • Nong Xu

    Original Article 11 March 2010 Pages: 147 - 152

    

19. Hyaluronan-Irinotecan improves progression-free survival in 5-fluorouracil refractory patients with metastatic colorectal cancer: a randomized phase II trial

    • Peter Gibbs
    • Philip R. Clingan
    • Tracey J. Brown

    Original Article 24 March 2010 Pages: 153 - 163

    

20. Oral bioavailability of DN101, a concentrated formulation of calcitriol, in tumor-bearing dogs

    • Kenneth M. Rassnick
    • Josephia R. Muindi
    • Donald L. Trump

    Original Article 21 March 2010 Pages: 165 - 171

    

21. Ultrasound-guided intratumoral administration of collagenase-2 improved liposome drug accumulation in solid tumor xenografts

    • Xiangpeng Zheng
    • Beth A. Goins
    • Gary D. Fullerton

    Original Article 21 March 2010 Pages: 173 - 182

    

22. Imexon enhances gemcitabine cytotoxicity by inhibition of ribonucleotide reductase

    • Nicholas O. Roman
    • Betty K. Samulitis
    • Robert T. Dorr

    Original Article 26 March 2010 Pages: 183 - 192

    

23. Everolimus and PTK/ZK show synergistic growth inhibition in the orthotopic BL16/BL6 murine melanoma model

    • Terence O’Reilly
    • Heidi A. Lane
    • Paul M. J. McSheehy

    Original Article 30 May 2010 Pages: 193 - 200

    

24. Streptomycin alleviates irinotecan-induced delayed-onset diarrhea in rats by a mechanism other than inhibition of β-glucuronidase activity in intestinal lumen

    • Akinobu Kurita
    • Shoichi Kado
    • Teruo Yokokura

    Original Article 31 March 2010 Pages: 201 - 213

    

25. Phase II study of a fixed dose-rate infusion of gemcitabine associated with erlotinib in advanced pancreatic cancer

    • J. Feliu
    • P. Borrega
    • M. González-Barón

    Clinical Trial Report 07 October 2010 Pages: 215 - 221

    

26. Fulvestrant 250 mg versus anastrozole for Chinese patients with advanced breast cancer: results of a multicentre, double-blind, randomised phase III trial

    • Binghe Xu
    • Zefei Jiang
    • Junlan Yang

    Clinical Trial Report 12 October 2010 Pages: 223 - 230

    

27. Effects of methimazole on the elimination of irinotecan

    • Jessica M. van der Bol
    • Theo J. Visser
    • Ron H. J. Mathijssen

    Short Communication Open access 01 August 2010 Pages: 231 - 236

    

28. The small-molecule tyrosine kinase inhibitor nilotinib is a potent noncompetitive inhibitor of the SN-38 glucuronidation by human UGT1A1

    • Ken-ichi Fujita
    • Minako Sugiyama
    • Yasutsuna Sasaki

    Short Communication 02 September 2010 Pages: 237 - 241

    

29. Cytokeratin 8/18 monoclonal antibody was dissimilar to anti-cytokeratin CAM 5.2

    • Shao-Chuan Wang
    • Fong-Lin Chen
    • Chih-Ping Han

    Letter to the Editor 14 December 2010 Pages: 243 - 244

30. In response to Dr. Han’s comments

    • Mattheos Bobos
    • Aristotelis Bamias

    Letter to the Editor 20 November 2010 Pages: 245 - 245